IN2012DN00167A - - Google Patents
Info
- Publication number
- IN2012DN00167A IN2012DN00167A IN167DEN2012A IN2012DN00167A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A IN 167DEN2012 A IN167DEN2012 A IN 167DEN2012A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A
- Authority
- IN
- India
- Prior art keywords
- treatment
- compositions
- concerned
- methods
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00167A true IN2012DN00167A (de) | 2015-04-17 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN167DEN2012 IN2012DN00167A (de) | 2009-06-16 | 2010-06-16 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (de) |
| EP (1) | EP2442832B1 (de) |
| JP (1) | JP5646617B2 (de) |
| CN (1) | CN102458476B (de) |
| AU (1) | AU2010260585B2 (de) |
| BR (1) | BRPI1009606A2 (de) |
| CA (1) | CA2688766C (de) |
| CY (1) | CY1115714T1 (de) |
| DK (1) | DK2442832T3 (de) |
| ES (1) | ES2521565T3 (de) |
| HK (1) | HK1167101A1 (de) |
| HR (1) | HRP20141035T1 (de) |
| IL (1) | IL216993A (de) |
| IN (1) | IN2012DN00167A (de) |
| MX (1) | MX2011013661A (de) |
| NZ (1) | NZ577731A (de) |
| PL (1) | PL2442832T3 (de) |
| PT (1) | PT2442832E (de) |
| SI (1) | SI2442832T1 (de) |
| SM (1) | SMT201400165B (de) |
| WO (1) | WO2010147484A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5569944B2 (ja) * | 2008-04-01 | 2014-08-13 | イネイト・イムノセラピューティクス・リミテッド | 抗感染薬およびその使用 |
| LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| KR20170041116A (ko) * | 2015-10-06 | 2017-04-14 | 이네이트 이뮤노테라퓨틱스 리미티드 | 신경계의 보호 및/또는 복구용 조성물 및 방법 |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2019218079A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| US20210169904A1 (en) * | 2018-07-03 | 2021-06-10 | University Of Florida Research Foundation, Incorporated | Microparticle systems and their use for the treatment of multiple sclerosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU732809B2 (en) * | 1996-10-10 | 2001-05-03 | Innate Immunotherapeutics Limited | Compositions and methods for treating viral infections |
| AU2005259726A1 (en) * | 2004-07-01 | 2006-01-12 | Kobenhavns Universitet | Method for multiple sclerosis treatment and prophylaxis by treatment of Leptospira infection |
| WO2008070564A1 (en) | 2006-12-01 | 2008-06-12 | The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services | Uses of muramyl dipeptide (mdp) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/de active Active
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en active Application Filing
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2012
- 2012-08-10 HK HK12107888.6A patent/HK1167101A1/xx not_active IP Right Cessation
-
2014
- 2014-10-27 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2442832T3 (da) | 2014-11-10 |
| CY1115714T1 (el) | 2017-01-25 |
| MX2011013661A (es) | 2012-05-22 |
| AU2010260585B2 (en) | 2013-02-21 |
| US20100317589A1 (en) | 2010-12-16 |
| CN102458476A (zh) | 2012-05-16 |
| AU2010260585A8 (en) | 2012-06-14 |
| SI2442832T1 (sl) | 2014-12-31 |
| JP5646617B2 (ja) | 2014-12-24 |
| PL2442832T3 (pl) | 2015-01-30 |
| HK1167101A1 (en) | 2013-02-01 |
| WO2010147484A8 (en) | 2012-07-19 |
| EP2442832A1 (de) | 2012-04-25 |
| WO2010147484A1 (en) | 2010-12-23 |
| CN102458476B (zh) | 2014-08-20 |
| IL216993A0 (en) | 2012-02-29 |
| BRPI1009606A2 (pt) | 2016-10-11 |
| JP2012530132A (ja) | 2012-11-29 |
| EP2442832A4 (de) | 2013-07-03 |
| CA2688766C (en) | 2015-06-30 |
| PT2442832E (pt) | 2014-11-11 |
| AU2010260585A1 (en) | 2012-01-19 |
| NZ577731A (en) | 2010-08-27 |
| ES2521565T3 (es) | 2014-11-12 |
| EP2442832B1 (de) | 2014-08-06 |
| SMT201400165B (it) | 2015-01-15 |
| HRP20141035T1 (hr) | 2014-12-19 |
| US8389479B2 (en) | 2013-03-05 |
| CA2688766A1 (en) | 2010-12-16 |
| IL216993A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00167A (de) | ||
| MX2012006549A (es) | Composiciones y metodos que comprenden variantes de proteasa. | |
| MX2018009945A (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
| PH12014500053A1 (en) | Proteasome inhibitors | |
| EP2464724A4 (de) | Zusammensetzungen und verfahren zur implantierung von bearbeitetem fettgewebe und produkten aus bearbeitetem fettgewebe | |
| IN2012DN03883A (de) | ||
| JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
| MY179933A (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof | |
| MX346801B (es) | Métodos y composiciones para trastornos relacionados con la proliferación celular. | |
| IN2012DN00971A (de) | ||
| JO2860B1 (en) | Phenylendazolyl compounds | |
| MX2011013577A (es) | Composiciones y metodos para tratar esclerosis lateral amiotrofica. | |
| MX2013004906A (es) | Nuevos inhibidores especificos de la proteasa ns3 de hcv. | |
| MX2011008179A (es) | Peptidos para vacuna. | |
| MX361692B (es) | Inhibidores de amida hidrolasa de ácido graso. | |
| EP2566485A4 (de) | Immunstimulationszusammensetzungen und verwendungsverfahren dafür | |
| EP2597949A4 (de) | Submikrometerzusammensetzungen | |
| EP2445873A4 (de) | Proteasehemmer, zusammensetzungen daraus und verfahren zu ihrer verwendung | |
| MY161460A (en) | Elastomeric dental floss | |
| MX2011010046A (es) | Derivados de diaminopteridina. | |
| MX2012012509A (es) | Tapentadol para usarse en el tratamiento del sindrome del intestino irritable. | |
| TN2011000041A1 (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| MY180594A (en) | Proteasome inhibitors | |
| GEP20146006B (en) | Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3- dimethyl-butyramide | |
| UA42373U (en) | Use of taurin and jacton as antioxidant and genome protector |